Why is there never a headline that says "Government program ends as its intended goal has been achieved"?"- Oleg Atbashian
Today, we look at an oncology concern from across the pond. The company recently came public, and like so many IPOs in the biotech sector these days, its IPO soon became 'busted' and is down since it made its debut on the market. However, it has some 'shots on goal' and merited further investigation.
Company Overview
Autolus Therapeutics plc (AUTL) is a London-based, early-stage biopharmaceutical concern focused on the treatment of cancer through its